Shares of Veru Inc. soared nearly 200 percent after the Florida-based company announced its Phase III COVID-19 antiviral treatment was halted early based on positive efficacy following an Independent Data Monitoring Committee’s recommendation.
Alexion, the unit within global pharmaceutical firm AstraZeneca that focuses on finding treatments for rare diseases, is halting clinical trials for Ultomiris (ravulizumab) for adults with amyotrophic lateral sclerosis.
GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.
Genentech reported that the company’s rheumatoid arthritis drug Actemra failed to hit the primary endpoint in a Covid-19 trial, while Vir and GlaxoSmithKline’s antibody against Covid-19 demonstrated 85 percent efficacy.
China’s CanSino Biologics Inc. said an independent committee found the drugmaker’s Covid-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of Phase 3 trial data.
Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.